10-K: Decoy Therapeutics Navigates Nasdaq Listing, Advances AI-Driven Pipeline

Decoy Therapeutics Inc. reports a significant net loss for 2025, addresses Nasdaq delisting concerns with a reverse stock split, and advances its AI-driven peptide conjugate pipeline following a strategic merger.

Summary

• Decoy Therapeutics Inc. (formerly Salarius Pharmaceuticals, Inc.) is a preclinical-stage biotechnology company focused on peptide conjugate therapeutics using its proprietary IMP3ACT platform, initially targeting infectious diseases and oncology.
• The company completed a merger with Legacy Decoy on November 12, 2025, and subsequently changed its name to Decoy Therapeutics Inc. on January 8, 2026.
• A net loss of $12.5 million was reported for the year ended December 31, 2025, an increase from $5.6 million in 2024, primarily due to acquired in-process research and development expenses from the merger.
• The company received a Nasdaq delisting notice on December 31, 2025, for failing to meet the $1.00 minimum bid price requirement but regained compliance by March 20, 2026, after a 1-for-12 reverse stock split effective March 6, 2026.
• A public offering in November 2025 generated approximately $6.3 million in net proceeds.
• The company's lead program, a pan-Coronavirus prophylactic, is in late lead optimization, with an Investigational New Drug (IND) application planned for the first half of 2027.
• Decoy Therapeutics has never generated revenue from product sales and has an accumulated deficit of $94.4 million as of December 31, 2025, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk, early-stage biotechnology company with promising technology but significant financial challenges. While the merger and AI platform offer long-term potential, the substantial net loss, accumulated deficit, and going concern warning indicate immediate operational and funding hurdles.

Positives

• Successfully regained compliance with Nasdaq's minimum bid price requirement by March 20, 2026, following a reverse stock split.
• Completed a strategic merger with Legacy Decoy, integrating a proprietary IMP3ACT platform leveraging machine learning and AI for accelerated drug discovery.
• Secured approximately $6.3 million in net proceeds from a public offering in November 2025, providing capital for operations.
• Received significant non-dilutive funding, including approximately $4.4 million from The Gates Foundation (with $0.6 million expected in H1 2026) and multiple awards from Johnson & Johnson Innovation LLC.
• Advanced its lead pan-Coronavirus prophylactic program to late lead optimization, with an IND application planned for the first half of 2027.
• Demonstrated promising preclinical data for its pan-Coronavirus D-MAV, showing in vitro activity against all human-infecting Coronaviruses tested and in vivo efficacy in Syrian hamster models.
• Developed a novel 'All-in-One' manufacturing process for peptide conjugates, aiming for faster and lower-cost production.
• SP-2577, a legacy small molecule, had its partial clinical hold lifted by the FDA in February 2025, and patient enrollment resumed before ending in January 2026.

Negatives

• Reported a significant net loss of $12.5 million for the year ended December 31, 2025, an increase from $5.6 million in 2024.
• Accumulated deficit reached $94.4 million as of December 31, 2025.
• The company has never generated revenue from product sales and does not anticipate doing so for several years, if ever.
• The independent registered public accounting firm included an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern.
• Existing cash and cash equivalents of $10.7 million (including $3.0 million restricted) are only sufficient to fund operations into late 2026, necessitating substantial additional capital.
• The merger with Legacy Decoy triggered a Nasdaq Change of Control, requiring the company to satisfy all initial listing criteria and obtain stockholder approval for preferred stock conversion, which may be challenging.
• The SP-2577 program has ended patient enrollment and the company intends to seek strategic alternatives, including potential out-licensing, indicating a shift away from this legacy asset.
• The company's stock has been subject to delisting procedures due to low bid price, requiring multiple reverse stock splits (1-for-15 in August 2025, 1-for-12 in March 2026).

Risks

• Nasdaq may delist securities from trading on its exchange, which could limit investors' ability to make transactions and subject the company to additional trading restrictions.
• The company's financial condition raises substantial doubt regarding its ability to continue as a going concern.
• The company has never generated revenue from product sales, and all potential product candidates are currently in the preclinical stage, leading to expected significant losses for the foreseeable future.
• It is difficult to evaluate the company's prospects and the likelihood of success or failure due to the lack of revenue from product sales.
• Early-stage drug development requires major capital investment, and the company will need to raise additional capital or form strategic partnerships, which may not be available on acceptable terms or at all.
• Future sales of a significant number of common stock shares in the public markets, or the perception of such sales, could depress the market price and impair the ability to raise capital.
• The company may become involved in securities class action litigation that could divert management's attention and harm the business, with potentially insufficient insurance coverage.
• Strategic alliances on which the company depends may be unsuccessful or terminated, hindering development or commercialization of certain potential product candidates and revenue generation.
• Reliance on third parties to conduct, supervise, and monitor future clinical trials poses risks if those third parties fail to perform satisfactorily or meet regulatory requirements.
• The novel approach to drug discovery, including the usage of AI, may never lead to marketable products, and the company is subject to unique risks related to evolving AI regulations, third-party technology dependencies, intellectual property concerns, and cybersecurity threats.
• Even if FDA grants breakthrough therapy designation for potential product candidates, the designation may not lead to faster development or regulatory review/approval, and FDA may rescind it.
• Failure to identify or discover additional potential product candidates could result in loss of investment.
• Potential product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences post-marketing approval.
• Difficulty in enrolling patients is a common hurdle that could delay or prevent clinical trials.
• Inability to obtain or protect intellectual property rights related to future products and potential product candidates may hinder competitive effectiveness.
• Trade secrets and confidential proprietary information may be disclosed, and competitors may gain access or independently develop substantially equivalent information and techniques.
• Third-party claims of intellectual property infringement may prevent or delay development and commercialization efforts.
• Inability to protect intellectual property rights throughout the world.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties could prevent revenue generation from product sales.
• Loss of key management or scientific personnel, inability to recruit qualified employees, or increases in compensation costs could materially harm the business.
• Commercialization of approved products outside the United States involves risks associated with international operations.
• Potential product liability claims could result in substantial liability and costs exceeding insurance coverage.
• The price of common stock may fluctuate substantially due to various factors.
• No current intention to pay dividends on common stock; any return to investors is expected only from potential increases in stock price.
• Risk of being deemed an investment company under the Investment Company Act of 1940, which could make business impractical.
• As a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
• Anti-takeover effects in the certificate of incorporation, bylaws, and Delaware law could discourage, delay, or prevent a change in control.
• Financial reporting obligations of being a public company are expensive and time-consuming, requiring substantial management time.
• If securities or industry analysts do not publish research or publish unfavorable reports, stock price and trading volume may decline.
• Failure to comply with Sarbanes-Oxley Act rules related to accounting controls and procedures, or discovery of material weaknesses, could significantly decline stock price and make capital raising difficult.
• Changes in tax laws or exposure to additional income tax liabilities could have a material impact on business, results of operations, financial condition, and cash flows.
• Additional indirect taxes in various jurisdictions could materially adversely affect business.
• Business interruptions resulting from natural disasters and adverse weather events could cause delays in research and development.
• Cybersecurity threats and other security threats and disruptions could negatively impact the business.

Future Outlook

Decoy Therapeutics plans to file an Investigational New Drug (IND) application for its lead pan-Coronavirus prophylactic program in the first half of 2027, aiming for Phase 1 clinical trials shortly thereafter, followed by a Phase 2a human challenge study. The company intends to continue seeking non-dilutive funding and development partners for clinical advancement and aims to bring one additional transformative program to IND-enabling status within two years. It also plans to explore strategic alternatives, including out-licensing, for its legacy SP-2577 program.

Management Comments

• We believe the synergies from the Merger are evident in our combined approach to drug development, integrating expertise in peptide conjugates with our small molecule assets. This combination enables us to address a wider range of diseases and potentially undruggable targets.
• Our IMPACT platform creates peptides that target what enveloped viruses share, integrating AI-enabled peptide design with rapid synthesis to advance candidates faster than traditional approaches.
• We believe this target selection strategy will maximize return on investment from the IMP3ACT platform by efficiently advancing paradigm-creating D-MAVs, changing the way we protect against and treat viral diseases.
• We believe the IMP3ACT platform has several key advantages compared to other drug-discovery approaches: Proprietary Data, Faster & Lower Cost Discovery, Streamlined & Repeatable Manufacturing, Low Commercial Cost of Goods, Flexible Formulation, Increased Probability of Success.
• We believe there is reasonable probability the fusion inhibitor will show similar activity against measles and Nipah in vitro, though this cannot be confirmed until relevant experiments are performed.
• We believe our tripledemic D-MAV antiviral program could represent the cornerstone of a significant global franchise.
• We believe our strategy of treating all three viruses—and potentially additional human Coronaviruses and Paramyxoviruses causing influenza-like symptoms—with a single therapeutic will deliver a unique value proposition during seasonal ILI surges.
• We believe it will be feasible to build a small, specialized sales force working across our portfolio to target these patient settings in a financially efficient manner, driving revenue while maintaining cost-effective commercial and medical affairs footprints.
• We believe we will be well-positioned to implement an innovative commercialization strategy leveraging emerging technologies to optimize patient engagement, HCP access, and product delivery.

Industry Context

StockSavvy.ai notes that Decoy Therapeutics' focus on AI-driven peptide conjugate therapeutics aligns with a growing trend in the biotechnology sector to leverage advanced computational methods for accelerated drug discovery. The emphasis on broad-spectrum antivirals for respiratory viruses like Coronaviruses, Flu, and RSV addresses a significant and persistent global health challenge, particularly in immunocompromised populations, a market segment where existing solutions often face limitations such as drug-drug interactions (e.g., Paxlovid) or rapid viral evolution (e.g., antibody prophylactics like Evusheld and pemivibart). The company's strategy to pursue non-dilutive funding and partnerships for clinical development is common for preclinical biopharmaceutical firms aiming to mitigate capital intensity.

Comparison to Industry Standards

• The company's 'All-in-One' manufacturing process aims to reduce peptide conjugate synthesis from several months (typical at a standard CDMO) to days or hours, significantly outperforming traditional industry timelines.
• The goal to manufacture 30g of active pharmaceutical ingredient (API) of a new therapeutic candidate in 30 days aims to meet or exceed the 100-day goal for vaccine manufacturing, positioning it favorably against conventional biopharmaceutical production.
• Targeting total Cost of Goods Sold (COGS) of less than $1/dose for its lead pan-Coronavirus inhibitor program is highly competitive, especially compared to the $1,390 list price for a 5-day course of Paxlovid.
• The company's preclinical stage pipeline and lack of revenue from product sales are typical for early-stage biotechnology companies, but the substantial accumulated deficit of $94.4 million and going concern warning indicate a higher financial risk profile compared to more advanced or revenue-generating peers.
• The FDA's reported success rates for drugs proceeding past Phase 1 (70%), Phase 2 (33%), and Phase 3 (25-30%) highlight the inherent high risk of drug development, which Decoy Therapeutics, as a preclinical company, is fully exposed to.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings the outcome of which, if determined adversely, would individually or in the aggregate, have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• One officer/founder had an outstanding Demand Note of $55,555 plus $13,000 accrued interest as of December 31, 2025, to be exchanged for Salarius Series B Preferred Stock.
• One family member of an officer/founder had an outstanding Demand Note of $83,333 plus $22,000 accrued interest, and an outstanding Promissory Note of $100,000 plus $20,000 accrued interest as of December 31, 2025, both to be exchanged for Salarius Series B Preferred Stock.
• Founders of Legacy Decoy loaned Legacy Decoy approximately $140,000 through non-interest bearing, open-ended maturity notes during H2 2024 and H1 2025, amended to mature in November 2026.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future capital raises; stock price volatility due to financial condition and delisting risks; potential for long-term value creation if pipeline candidates succeed; limited voting rights for preferred stock holders until conversion.
• Employees: Continued employment for 11 full-time employees and contractors; potential for increased compensation costs due to competition for qualified personnel; impact of management changes on team dynamics.
• Customers (future patients): Potential for novel peptide conjugate therapeutics to address unmet medical needs in infectious diseases and oncology, offering new treatment options.
• Suppliers/Partners: Continued reliance on third-party CROs and CMOs for R&D and manufacturing; potential for new collaborations for scale-up and commercialization.
• Creditors: Risk associated with the company's 'going concern' warning and need for additional capital.

Next Steps

• File an Investigational New Drug (IND) application with the FDA or European equivalent CTA for the pan-Coronavirus prophylactic program during the first half of 2027.
• Initiate a Phase 1 clinical trial for the pan-Coronavirus prophylactic shortly after IND approval.
• Conduct a Phase 2a human challenge study for the pan-Coronavirus prophylactic.
• Continue to pursue non-dilutive funding and a development partner for the pan-Coronavirus prophylactic program.
• Bring one additional transformative program to IND-enabling status within two years.
• Build a platform manufacturing capability, including pursuing collaborations with major commercial peptide manufacturing organizations.
• Continue to access non-dilutive funding from governmental and non-governmental organizations.
• Pursue value-enhancing partnerships for later-stage development and commercialization.
• Maintain pandemic readiness by rapidly advancing antiviral therapeutics in response to novel viral pathogens.
• Seek strategic alternatives, including potential out-licensing, for the legacy SP-2577 program.
• Integrate SP-3164 to expand opportunities in creating peptide-based proteolysis targeting chimeras (P-PROTACs).
• Commence the Nasdaq initial listing process following the consummation of the November 2025 financing and the Merger Closing, at such time that the post-transaction entity is expected to satisfy all applicable Nasdaq initial listing criteria.

Key Dates

Recommendation

Decoy Therapeutics faces severe financial distress, evidenced by a substantial net loss, accumulated deficit, and an explicit 'going concern' warning from both management and auditors. While the strategic merger and AI-driven platform offer long-term potential, the immediate need for significant additional capital, coupled with the inherent high risks of preclinical drug development and past Nasdaq delisting issues, presents an extremely speculative investment. The company has no revenue from product sales and does not expect any for years, making it highly vulnerable to funding shortfalls and further dilution. A seasoned investor would recognize the significant downside risk and recommend a strong sell.

Keywords

Biotechnology, Peptide Conjugates, AI Drug Discovery, Machine Learning, Preclinical Development, Infectious Diseases, Oncology, Nasdaq Listing, Reverse Stock Split, SEC Filing, Drug Development, Financial Reporting, Corporate Governance, Risk Management, Strategic Merger, Capital Raise, Pharmaceuticals, Antivirals, COVID-19, Flu, RSV, PROTACs, Intellectual Property